Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CC-91633-AML-001  |   NCT04951778

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18+
    Age Range
  • 19
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 doses (RP2D) and schedule. Throughout the study, final decisions on dose escalation/de-escalation will be made by the safety review committee (SRC). Approximately 60 participants may be enrolled in Part A of the study. The expansion part (Part B) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development. Approximately 60 response-evaluable subjects per indication (R/R AML or R/R HR-MDS) may be enrolled. Parts A and B will consist of 3 periods: Screening, Treatment, and Follow-up.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
: Participants must satisfy the criteria below to be enrolled in the Dose Escalation (Part A) or the Dose Expansion (Part B) of this study.
  • Participant is ≥ 18 years of age, at the time of signing the ICF.
    1. Participant must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
      1. Participant is willing and able to adhere to the study visit schedule and other protocol requirements.
        1. Relapsed or refractory acute myeloid leukemia (R/R AML) and relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS) as defined by the World Health Organization (WHO) criteria who have failed or are ineligible for all available therapies which may provide clinical benefit
          1. Participant has Eastern Cooperative Oncology Group Performance Status of 0 to 2.
            1. Participants must have the following screening laboratory values:
              1. Total White Blood Cell count (WBC) < 25 x 109/L prior to first infusion.
                1. Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≤ 3.0 x upper limit of normal (ULN), unless considered due to leukemic organ involvement, in which case AST and ALT can be ≤ 5.0 x ULN.
                  1. Uric acid ≤ 7.5 mg/dL (446 μmol/L).
                    1. Serum total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome
                      1. Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated.
                        1. INR < 1.5 x ULN and partial thromboplastin time (PTT) < 1.5 x ULN.

                          Exclusion Criteria

                          Exclusion Criteria Icon
                          : The presence of any of the following will exclude a participant from enrollment:
                          • Participant has any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, which places the participant at unacceptable risk if the participant were to participate in the study.
                            1. Any other significant medical condition, laboratory abnormality, or psychiatric illness which places the participant at unacceptable risk if he/she were to participate in the study or that would prevent the participant from complying with the study.
                              1. Participant has any condition that confounds the ability to interpret data from the study.
                                1. Participants with acute promyelocytic leukemia.
                                  1. Participants with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia.
                                    1. Participants with immediately life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection, uncontrolled bleeding, and/or uncontrolled disseminated intravascular coagulation.
                                      1. Participants with impaired cardiac function or clinically significant cardiac diseases,
                                        1. Participants who have undergone major surgery ≤ 2 weeks prior to starting CC-91633. Participants must have recovered from any clinically significant effects of recent surgery.
                                          1. Pregnant or nursing individuals.
                                            1. Participants with known human immunodeficiency virus infection.
                                              1. Participants with known chronic, active hepatitis B virus or hepatitis C virus C (HCV) infection.
                                                1. Participants with ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors).
                                                  1. Participants with history of concurrent second cancers requiring active, ongoing systemic treatment
                                                    1. Participants with clinically significant diarrhea, vomiting or malabsorption felt to limit absorption of orally administered medications.
                                                      1. Participants with known or suspected hypersensitivity to any of the components or excipients of the study treatment or to similar class drugs (eg, lenalidomide).
                                                        Additional Information *

                                                        Treatment Options

                                                        Study Arms

                                                        ASSIGNED INTERVENTION

                                                        Study Arms

                                                        Experimental: Participants with R/R AML and R/R HR-MDS - Part A

                                                        ASSIGNED INTERVENTION
                                                        • Drug: CC-91633

                                                        Study Arms

                                                        Experimental: Participants with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

                                                        ASSIGNED INTERVENTION
                                                        • Drug: CC-91633

                                                        Study Arms

                                                        Experimental: Participants with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (HR-MDS)

                                                        ASSIGNED INTERVENTION
                                                        • Drug: CC-91633
                                                        Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                                                        Check Your Eligibility
                                                        Answer some questions about Your health to see if you may match to this trial
                                                        Match to a Trial
                                                        If you are a match, click on the study to see the list of study site locations
                                                        Select a Study Site Location
                                                        Select a study site location that is convenient for you
                                                        Register
                                                        Provide your contact details for the study site to connect with you.

                                                        Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you